BCAM Antibody

What is BCAM and why is it important in cancer research?

BCAM (Basal Cell Adhesion Molecule), also known as CD239 or Lutheran blood group glycoprotein, is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It functions as both a receptor and an adhesion molecule, playing crucial roles in cell adhesion, motility, migration, and invasion . Its importance in cancer research stems from evidence suggesting that BCAM expression levels correlate with immunotherapy responsiveness. Notably, patients with low BCAM expression show hypermethylation at multiple immune checkpoints, potentially indicating better responses to immune checkpoint inhibitors (ICIs) . BCAM has been implicated in the progression of various malignancies including ovarian, pancreatic, thyroid, and gastric cancers .

What is the molecular structure of BCAM and how does it function?

BCAM is a type I transmembrane glycoprotein with a molecular weight of approximately 67 kDa in its de-glycosylated form, though it typically appears at 78-85 kDa in its glycosylated state . Structurally, full-length BCAM comprises:

• An extracellular region with two N-terminal V-type Ig-like domains followed by three C2-type Ig-like domains

• A transmembrane region

• A cytoplasmic domain of 59 amino acid residues

Functionally, the extracellular domain enables binding to extracellular matrix proteins, particularly laminin α5 (LAMA5), while its intracellular domain interacts with cytoskeletal proteins like hemoglobin, facilitating signal transduction . Mechanistically, JAK2 induces BCAM phosphorylation and activates its adhesion to laminin by stimulating a Rap1/AKT signaling pathway .

What are the common applications of BCAM antibodies in research?

BCAM antibodies are utilized across multiple experimental approaches:

These applications enable researchers to investigate BCAM expression patterns, localization, and functional interactions in various experimental contexts .

How can BCAM antibodies be used to investigate the correlation between BCAM expression and immune checkpoint profiles?

To investigate correlations between BCAM expression and immune checkpoint profiles, researchers can employ a multi-faceted approach:

• Quantitative Immunofluorescence (QIF): Using the validated antibody (e.g., AB111181 at 1 μg/ml concentration), researchers can quantify BCAM expression in tumor tissues alongside immune checkpoint markers (CD274, CTLA4, HAVCR2, LAG3, PDCD1, PDCD1LG2, and TIGIT) .

• Correlation Analysis Protocol:

  • Perform sequential staining on serial sections using BCAM antibody and immune checkpoint antibodies

  • Quantify expression using AQUA scores by dividing the sum of target pixel staining intensities by the area of the designated compartment

  • Generate BCAM-high and BCAM-low subgroups based on expression quartiles

  • Analyze methylation patterns of immune checkpoint genes in both subgroups

  • Correlate BCAM expression with PD-L1 expression to establish potential predictive value for immunotherapy response

This methodology has revealed that multiple immune checkpoints are overexpressed in patients with low BCAM expression, with lower methylation levels in the BCAM-low subgroup compared to the BCAM-high subgroup, suggesting better response to ICI therapy .

What methodological approaches are recommended for validating a BCAM antibody for specific research applications?

Antibody validation requires systematic evaluation of specificity and reliability:

• Signal-to-Noise Ratio (SNR) Determination:

  • Test multiple antibodies targeting different epitopes (e.g., comparing commercial options like AB111181, MCA 1982, MM0107, FQS5276, HPA005654, and biotinylated antibodies)

  • Calculate SNR using control cell lines with known BCAM expression profiles

  • For tumor tissues, calculate SNR by comparing the average AQUA score of the 10% highest expressing spots to the 10% lowest expressing spots

• Concentration Optimization:

  • Perform titration experiments across a range of concentrations

  • Determine optimal concentration based on SNR peak (e.g., 1 μg/ml for AB111181)

• Cross-Validation Approaches:

  • Western blot analysis of cell lines with varying BCAM expression levels

  • Competition assays using labeled and unlabeled antibodies

  • ELISA with recombinant BCAM protein

  • Cross-reactivity testing with related proteins

How can BCAM antibodies be utilized in developing targeted cancer therapeutics?

BCAM antibodies have shown promising potential in developing targeted cancer therapeutics through several strategies:

• Antibody-Drug Conjugates (ADCs):

  • GENA-111, a human monoclonal anti-BCAM IgG4 (S228P) antibody, demonstrates high affinity binding to human BCAM and significant internalization by BCAM-positive tumor cells

  • When conjugated to auristatin F using novel linker technology, GENA-111-auristatin F ADC shows potent cytotoxic effects on BCAM-expressing tumor cells

  • Cytotoxicity correlates positively with BCAM expression levels

  • In xenograft mouse models using A431 cells (BCAM-positive human skin cancer cell line), this ADC significantly reduces tumor growth

• Target Identification and Validation:

  • The Phenotypic Antibody and Simultaneous Target (PhAST)-discovery platform utilizes bacteriophage display-based Single variable domain on a heavy chain (VHH) library to select antibodies with desired cell surface binding specificity

  • This approach allows simultaneous discovery of multiple antibody-target pairs specific to cancer cells

  • Mass spectrometric identification of antibody targets provides valuable insights for therapeutic development

• Antibody-Dependent Cellular Cytotoxicity (ADCC):

  • ADCC assays demonstrate that anti-BCAM antibodies can recruit immune effector cells to eliminate BCAM-expressing cancer cells

  • Protocol involves staining target cells with CellTrace Violet, incubating with antibodies, adding IL-2 stimulated PBMCs, and assessing cell death via Annexin V staining

These approaches highlight the potential of BCAM antibodies as therapeutic agents, particularly for BCAM-positive epithelial cancers .

What factors should be considered when selecting a BCAM antibody for a specific experimental approach?

Selection of appropriate BCAM antibodies requires consideration of several critical factors:

Additionally, consider target subcellular localization (membrane, cytoplasmic) and expression level in your experimental system. For cancer studies, antibodies validated in relevant cancer cell lines (A431, HT-29, Huh7) are preferable .

What are common technical challenges when using BCAM antibodies and how can they be addressed?

Addressing these challenges through methodological optimization ensures reliable and reproducible results when working with BCAM antibodies.

How can researchers quantitatively assess BCAM expression in complex tissue samples?

Quantitative assessment of BCAM in complex tissues requires sophisticated approaches:

• Quantitative Immunofluorescence (QIF) Protocol:

  • Deparaffinize tissue sections and perform antigen retrieval

  • Block with BSA to reduce background

  • Incubate with primary antibody mixture (anti-BCAM + anti-cytokeratin)

  • Apply secondary antibodies (e.g., anti-rabbit Envision + anti-mouse Alexa Fluor 546)

  • Amplify signal with tyramide cyanine 5

  • Counterstain nuclei with DAPI

  • Mount slides with antifade reagent

• Compartmentalized Analysis Strategy:

  • Define distinct tissue compartments:

    • Total compartment: all cells (DAPI signal)

    • Tumor compartment: cytokeratin-positive areas

    • Stromal compartment: total minus tumor

  • Measure BCAM expression within the tumor mask/compartment

  • Calculate AQUA scores by dividing sum of target pixel intensities by compartment area

  • Average scores across multiple tumor spots for robust quantification

• Digital Pathology Approaches:

  • Scan stained slides on specialized imaging systems (e.g., Vectra 3)

  • Analyze using software platforms (e.g., Halo) with machine learning algorithms

  • Train algorithms to distinguish epithelial cells from stroma

  • Perform cell segmentation for single-cell analysis

  • Set thresholds based on staining intensity normalized to background

  • Define cells above threshold as BCAM-positive

These methodologies enable precise quantification of BCAM expression in heterogeneous tissue samples, allowing correlation with clinical outcomes and therapeutic responses.

How might BCAM antibodies contribute to personalized cancer therapy approaches?

BCAM antibodies show significant potential for advancing personalized cancer therapy:

• Predictive Biomarker Development:

  • Evidence suggests BCAM expression levels correlate with immune checkpoint expression and methylation patterns

  • Low BCAM expression is associated with hypermethylation at multiple immune checkpoints, potentially predicting favorable response to immunotherapy

  • Quantitative assessment of BCAM using validated antibodies could stratify patients for ICI therapy

• Targeted Therapeutic Approaches:

  • ADCs like GENA-111-auristatin F demonstrate cytotoxicity proportional to BCAM expression

  • Patient tumor samples could be screened for BCAM expression to select candidates for BCAM-targeted therapies

  • In vitro cytotoxicity examination shows correlation between therapeutic effect and BCAM expression level

• Combination Therapy Optimization:

  • BCAM expression data, when combined with PD-L1 assessment, may guide combination approaches

  • Patients with specific BCAM/PD-L1 expression patterns might benefit from dual targeting strategies

  • BCAM's role in cell adhesion and migration suggests potential for targeting both tumor growth and metastatic potential

These applications demonstrate how BCAM antibodies could facilitate patient selection and therapeutic design in precision oncology.

What recent technological innovations have enhanced the utility of BCAM antibodies in research?

Recent technological innovations have significantly expanded BCAM antibody applications:

• Novel Linker Technologies for ADCs:

  • New linker technologies comprising cleavable peptidic sequences facilitate multidrug attachment

  • Production of ADCs with tailored drug-to-antibody ratios (DARs)

  • Selective drug release through Cathepsin B carboxypeptidase activity

  • Stabilized thiol maleimide conjugation for improved ADC stability

• High-Throughput Antibody Discovery Platforms:

  • The PhAST-discovery platform enables unbiased, simultaneous discovery of antibodies and targets

  • Bacteriophage display-based VHH libraries allow selection for desired binding profiles

  • Mass spectrometric identification of antibody targets streamlines biomarker discovery

  • Flow cytometry-based multiplexed screening using differential cell labeling accelerates antibody validation

• Digital Pathology Integration:

  • Automated imaging systems like Vectra 3 combined with analysis software (Halo)

  • Machine learning algorithms for tissue compartment identification

  • Quantitative assessment of BCAM expression at single-cell resolution

  • Spatial analysis of BCAM in relation to immune infiltrates and other microenvironmental features

These innovations enhance the precision, throughput, and clinical relevance of BCAM antibody applications in both research and therapeutic development.

How does BCAM expression vary across different cancer types and what implications does this have for antibody-based research?

BCAM expression exhibits significant heterogeneity across cancer types with important research implications:

• Expression Patterns in Major Cancer Types:

  • Studies spanning seven cancer types and 3114 patients reveal distinct BCAM expression profiles

  • Overexpression observed in ovarian carcinomas compared to normal tissues

  • Elevated in clear cell renal cell carcinoma with correlation to immune checkpoint expression

  • Present in pancreatic cancer, identified as a potential biomarker through proteomics analysis

  • Functional role in metastasis of thyroid and gastric cancers

• Subcellular Localization Differences:

  • Predominantly membrane-localized in most epithelial cancers

  • Cell-line specific patterns observed in experimental models

  • Internalization kinetics vary by cell type, with implications for ADC efficacy

  • Requires consideration of appropriate antibody epitopes and detection methods

• Implications for Research Strategies:

  • Need for cancer type-specific validation of antibodies

  • Differential expression suggests varied therapeutic potential across cancer types

  • Requirement for comprehensive assessment in clinical samples before therapeutic development

  • Importance of combined analysis with other biomarkers for accurate patient stratification

Understanding these variations is essential for developing effective BCAM-targeted diagnostic and therapeutic approaches across different cancer types.